PL1648940T3 - Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A - Google Patents
Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem AInfo
- Publication number
- PL1648940T3 PL1648940T3 PL04777121.7T PL04777121T PL1648940T3 PL 1648940 T3 PL1648940 T3 PL 1648940T3 PL 04777121 T PL04777121 T PL 04777121T PL 1648940 T3 PL1648940 T3 PL 1648940T3
- Authority
- PL
- Poland
- Prior art keywords
- protein
- affinity chromatography
- reducing
- leaching during
- leaching
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49050003P | 2003-07-28 | 2003-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1648940T3 true PL1648940T3 (pl) | 2016-12-30 |
Family
ID=34193088
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04777121.7T PL1648940T3 (pl) | 2003-07-28 | 2004-06-24 | Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A |
PL16164203T PL3095793T3 (pl) | 2003-07-28 | 2004-06-24 | Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16164203T PL3095793T3 (pl) | 2003-07-28 | 2004-06-24 | Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A |
Country Status (14)
Country | Link |
---|---|
US (2) | US7485704B2 (pl) |
EP (3) | EP3722309A1 (pl) |
JP (1) | JP4599355B2 (pl) |
AU (1) | AU2004265253B2 (pl) |
CA (1) | CA2531595C (pl) |
DK (2) | DK3095793T3 (pl) |
ES (1) | ES2786568T3 (pl) |
HR (1) | HRP20200589T1 (pl) |
HU (2) | HUE050171T2 (pl) |
LT (1) | LT3095793T (pl) |
PL (2) | PL1648940T3 (pl) |
PT (1) | PT3095793T (pl) |
SI (2) | SI1648940T1 (pl) |
WO (1) | WO2005016968A2 (pl) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
DK3095793T3 (da) | 2003-07-28 | 2020-05-25 | Genentech Inc | Reducering af udvaskning af protein A under en protein A-affinitetskromatografi |
WO2005037869A2 (en) * | 2003-10-15 | 2005-04-28 | Applera Corporation | Method of reducing leachate from protein a affinity media |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US7483344B2 (en) | 2005-02-14 | 2009-01-27 | Quantum Corporation | Compact picker systems and methods for automated storage libraries |
ES2440481T3 (es) * | 2005-02-23 | 2014-01-29 | Genentech, Inc. | Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab |
WO2006110292A2 (en) * | 2005-03-25 | 2006-10-19 | The Regents Of The University Of California | Temperature-triggered immobilization and purification of antibodies |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US8940871B2 (en) | 2006-03-20 | 2015-01-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
BRPI0716762A2 (pt) | 2006-09-13 | 2013-09-24 | Abbott Lab | melhorias da cultura celular |
NZ577933A (en) * | 2007-01-22 | 2011-12-22 | Genentech Inc | Polyelectrolyte precipitation and purification of antibodies |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
KR20190140090A (ko) | 2007-07-09 | 2019-12-18 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
JP6126773B2 (ja) * | 2007-09-04 | 2017-05-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原(psca)抗体 |
EP2740490A1 (en) * | 2007-10-03 | 2014-06-11 | Cornell University | Treatment of proliferative disorders using antibodies to PSMA |
TWI472339B (zh) * | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
US9029508B2 (en) * | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
CN102027010A (zh) * | 2008-05-15 | 2011-04-20 | 诺沃-诺迪斯克有限公司 | 抗体纯化方法 |
PE20100092A1 (es) * | 2008-06-03 | 2010-03-12 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
PE20100054A1 (es) * | 2008-06-03 | 2010-03-03 | Abbott Lab | Inmunoglobulina con dominio variable dual |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
RU2011104348A (ru) * | 2008-07-08 | 2012-08-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение |
US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
MX2011001696A (es) * | 2008-08-14 | 2011-03-25 | Merck Sharp & Dohme | Metodos para purificar anticuerpos usando cromatografia de afinidad con proteina a. |
EP2335076B1 (en) * | 2008-09-15 | 2012-08-08 | EMD Millipore Corporation | Methods for quantifying protein leakage from protein based affinity chromatography resins |
CA2738499A1 (en) | 2008-10-20 | 2010-04-29 | Abbott Laboratories | Viral inactivation during purification of antibodies |
EP2921501A1 (en) | 2008-10-20 | 2015-09-23 | Abbvie Inc. | Isolation and purification of antibodies using Protein A affinity chromatography |
SG195555A1 (en) † | 2008-12-24 | 2013-12-30 | Emd Millipore Corp | Caustic stable chromatography ligands |
ES2712732T3 (es) * | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
CN102395597A (zh) | 2009-03-11 | 2012-03-28 | 惠氏有限责任公司 | 纯化小模块免疫药物蛋白的方法 |
MX346002B (es) | 2009-06-17 | 2017-03-01 | Abbvie Biotherapeutics Inc | Anticuerpos anti-vegf y sus usos. |
TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
WO2011015920A2 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A highly efficient process of purification and production of recombinant trastuzumab |
NZ598929A (en) * | 2009-09-01 | 2014-05-30 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
AR078651A1 (es) * | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
EP2506876B1 (en) | 2009-12-02 | 2016-10-12 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
US20130178608A1 (en) * | 2009-12-29 | 2013-07-11 | Samir Kulkarni | Protein purification by ion exchange |
US20130116413A1 (en) * | 2009-12-29 | 2013-05-09 | Dr. Reddy's Laboratories, Inc. | Purification of proteins |
WO2011153243A2 (en) * | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
MY160445A (en) | 2010-08-03 | 2017-03-15 | Abbvie Inc | Dual Variable Domain Immunoglobulins And Uses Thereof |
JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
US9051375B2 (en) | 2010-12-21 | 2015-06-09 | The University Of Western Ontario | Alkali-resistant variants of protein A and their use in affinity chromatography |
US9040661B2 (en) | 2010-12-21 | 2015-05-26 | Jsr Corporation | Support for affinity chromatography and method for isolating immunoglobulin |
CN104334189A (zh) | 2011-10-14 | 2015-02-04 | 霍夫曼-拉罗奇有限公司 | Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品 |
BR112014012539B1 (pt) | 2011-11-23 | 2022-12-20 | Medimmune, Llc | Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo |
EP2797955A2 (en) | 2011-12-30 | 2014-11-05 | AbbVie Inc. | Dual variable domain immunoglobulins against il-13 and/or il-17 |
JP6253584B2 (ja) * | 2012-08-27 | 2017-12-27 | 旭化成メディカル株式会社 | 温度応答性クロマトグラフィーによる抗体の精製方法 |
KR20210111353A (ko) | 2012-11-01 | 2021-09-10 | 애브비 인코포레이티드 | 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도 |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
EP2970459A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Dual specific binding proteins directed against il-1beta and il-17 |
NZ751877A (en) | 2013-04-16 | 2020-04-24 | Genentech Inc | Pertuzumab variants and evaluation thereof |
WO2014186350A1 (en) * | 2013-05-15 | 2014-11-20 | Medimmune Limited | Purification of recombinantly produced polypeptides |
WO2015009701A1 (en) | 2013-07-15 | 2015-01-22 | North Carolina State University | Protease-resistant peptide ligands |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
ES2737078T3 (es) * | 2013-09-04 | 2020-01-10 | Emd Millipore Corp | Cromatografía de Proteína A |
JP6602765B2 (ja) | 2013-09-05 | 2019-11-06 | ジェネンテック, インコーポレイテッド | クロマトグラフィー再使用のための方法 |
WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
KR101921552B1 (ko) * | 2014-03-10 | 2018-11-23 | 리히터 게데온 닐트. | 사전 세정 단계를 이용하는 면역글로불린 정제 |
WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
WO2015164665A1 (en) | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
EP3169801A1 (en) | 2014-07-14 | 2017-05-24 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for treatment of glioblastoma |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
AR104368A1 (es) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
CN107614015A (zh) | 2015-05-30 | 2018-01-19 | 豪夫迈·罗氏有限公司 | 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
EP4137158A1 (en) | 2015-08-07 | 2023-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
JP6851109B2 (ja) * | 2016-06-16 | 2021-03-31 | Jsr株式会社 | 抗体を精製する方法及び担体を洗浄する方法 |
AU2017355432A1 (en) | 2016-11-04 | 2019-05-16 | F. Hoffmann-La Roche Ag | Treatment of HER2-positive breast cancer |
TW201827077A (zh) | 2016-12-28 | 2018-08-01 | 美商建南德克公司 | 晚期her2表現癌症之治療 |
SI3570884T1 (sl) | 2017-01-17 | 2021-02-26 | Genentech, Inc. | Subkutane formulacije protiteles HER2 |
WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
CA3135846A1 (en) | 2019-04-02 | 2020-10-08 | Bondwell Technologies Inc. | Functionalized ubx protein materials for enhanced purification of antibodies |
EP4038349A4 (en) * | 2019-10-01 | 2022-12-28 | Repligen Corporation | DETERMINATION OF THE PROTEIN CONCENTRATION OF A FLUID |
US11224858B1 (en) | 2020-10-01 | 2022-01-18 | Immunicom, Inc. | Reduced leaching of a ligand |
AU2020470781A1 (en) | 2020-10-01 | 2023-05-18 | Immunicom, Inc. | Reduced leaching of a ligand |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US4983722A (en) | 1988-06-08 | 1991-01-08 | Miles Inc. | Removal of protein A from antibody preparations |
WO1989012463A1 (en) | 1988-06-21 | 1989-12-28 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
EP0602126B1 (en) | 1991-08-14 | 2003-03-05 | Genentech, Inc. | Immunoglobulin variants for specific fc epsilon receptors |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
CA2129663C (en) | 1992-02-06 | 2005-07-05 | James S. Huston | Biosynthetic binding protein for cancer marker |
WO1994004188A1 (en) | 1992-08-21 | 1994-03-03 | Genentech, Inc. | Method for treating an lfa-1-mediated disorder |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5714338A (en) | 1993-12-10 | 1998-02-03 | Genentech, Inc. | Methods for diagnosis of allergy |
MX9602818A (es) | 1994-01-18 | 1997-06-28 | Genentech Inc | Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige. |
US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
US5707622A (en) | 1994-03-03 | 1998-01-13 | Genentech, Inc. | Methods for treating ulcerative colitis |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
DE69505991T2 (de) | 1994-07-13 | 1999-04-08 | Sca Hygiene Paper Ab | Verfahren zur herstellung eines vliesstoffes |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
ES2183131T3 (es) | 1996-01-23 | 2003-03-16 | Genentech Inc | Anticuerpos anti-cd18 utilizados contra el ictus cerebral. |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
NO304183B1 (no) * | 1996-11-22 | 1998-11-09 | Nyfotek As | FremgangsmÕte for fremstilling av heksagonal faujasitt med lavt forbruk av organisk tilsetningsstoff, samt anvendelse av denne som katalysator ved alkylering |
DE69739673D1 (de) | 1996-11-27 | 2009-12-31 | Genentech Inc | Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix |
CA2272842C (en) | 1996-11-27 | 2012-05-15 | Genentech, Inc. | Humanized anti-cd11a antibodies |
ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
JP2001511653A (ja) | 1997-05-15 | 2001-08-14 | ジェネンテク,インコーポレイテッド | Apo−2レセプター |
ES2527915T3 (es) | 1998-06-09 | 2015-02-02 | Csl Behring Ag | Producto de inmunoglobulina G (IgG) líquido |
US6927044B2 (en) * | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
SI1189641T1 (sl) | 1999-06-25 | 2009-12-31 | Genentech Inc | Humanizirana protitelesa proti ErbB2 in zdravljenje s protitelesi proti ErbB2 |
DE60039448D1 (de) | 1999-10-29 | 2008-08-21 | Genentech Inc | Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung |
DE10155984A1 (de) | 2001-11-15 | 2003-05-28 | Boehringer Ingelheim Pharma | Verfahren zur Reduktion des Liganden-leakage von Affinitätschromatographie-Matrices |
EP2048154B2 (en) * | 2002-02-05 | 2015-06-03 | Genentech, Inc. | Protein purification |
DK1601697T3 (da) * | 2003-02-28 | 2007-10-01 | Lonza Biologics Plc | Oprensning af antistof ved protein A- og ionbytningskromatografi |
DK3095793T3 (da) | 2003-07-28 | 2020-05-25 | Genentech Inc | Reducering af udvaskning af protein A under en protein A-affinitetskromatografi |
US9813410B2 (en) | 2014-06-26 | 2017-11-07 | Rakuten, Inc. | Information processing apparatus, information processing method, and information processing program |
-
2004
- 2004-06-24 DK DK16164203.8T patent/DK3095793T3/da active
- 2004-06-24 ES ES16164203T patent/ES2786568T3/es not_active Expired - Lifetime
- 2004-06-24 PT PT161642038T patent/PT3095793T/pt unknown
- 2004-06-24 EP EP20158848.0A patent/EP3722309A1/en not_active Withdrawn
- 2004-06-24 PL PL04777121.7T patent/PL1648940T3/pl unknown
- 2004-06-24 SI SI200432332A patent/SI1648940T1/sl unknown
- 2004-06-24 EP EP04777121.7A patent/EP1648940B1/en not_active Revoked
- 2004-06-24 LT LTEP16164203.8T patent/LT3095793T/lt unknown
- 2004-06-24 AU AU2004265253A patent/AU2004265253B2/en not_active Expired
- 2004-06-24 US US10/877,532 patent/US7485704B2/en active Active
- 2004-06-24 HU HUE16164203A patent/HUE050171T2/hu unknown
- 2004-06-24 PL PL16164203T patent/PL3095793T3/pl unknown
- 2004-06-24 HU HUE04777121A patent/HUE029951T2/en unknown
- 2004-06-24 CA CA2531595A patent/CA2531595C/en not_active Expired - Lifetime
- 2004-06-24 EP EP16164203.8A patent/EP3095793B1/en not_active Expired - Lifetime
- 2004-06-24 WO PCT/US2004/020480 patent/WO2005016968A2/en active Application Filing
- 2004-06-24 SI SI200432496T patent/SI3095793T1/sl unknown
- 2004-06-24 JP JP2006521841A patent/JP4599355B2/ja not_active Expired - Lifetime
- 2004-06-24 DK DK04777121.7T patent/DK1648940T3/en active
-
2008
- 2008-11-12 US US12/269,752 patent/US7807799B2/en not_active Expired - Lifetime
-
2020
- 2020-04-14 HR HRP20200589TT patent/HRP20200589T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP1648940B1 (en) | 2016-04-27 |
EP3722309A1 (en) | 2020-10-14 |
HUE029951T2 (en) | 2017-04-28 |
US7485704B2 (en) | 2009-02-03 |
DK3095793T3 (da) | 2020-05-25 |
WO2005016968A3 (en) | 2005-04-21 |
EP3095793A1 (en) | 2016-11-23 |
SI3095793T1 (sl) | 2020-07-31 |
SI1648940T1 (sl) | 2016-08-31 |
CA2531595C (en) | 2015-12-08 |
JP2007526897A (ja) | 2007-09-20 |
DK1648940T3 (en) | 2016-08-15 |
US7807799B2 (en) | 2010-10-05 |
US20090099344A1 (en) | 2009-04-16 |
AU2004265253B2 (en) | 2011-09-01 |
WO2005016968A2 (en) | 2005-02-24 |
ES2786568T3 (es) | 2020-10-13 |
CA2531595A1 (en) | 2005-02-24 |
HRP20200589T1 (hr) | 2020-07-10 |
PT3095793T (pt) | 2020-05-04 |
HUE050171T2 (hu) | 2020-11-30 |
AU2004265253A1 (en) | 2005-02-24 |
US20050038231A1 (en) | 2005-02-17 |
JP4599355B2 (ja) | 2010-12-15 |
EP3095793B1 (en) | 2020-03-25 |
EP1648940A2 (en) | 2006-04-26 |
PL3095793T3 (pl) | 2020-09-07 |
LT3095793T (lt) | 2020-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1648940T3 (pl) | Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A | |
EP1693448A4 (en) | DOUBLE SPECIFICITY ANTIBODY FOR FUNCTIONAL PROTEIN SUBSTITUTION | |
TWI318229B (en) | Dyes having adapted affinity | |
HK1080089A1 (zh) | 鼠李糖結合蛋白 | |
GB0213760D0 (en) | A fusion protein | |
GB0201808D0 (en) | Protein | |
AU2003278718A8 (en) | Stars-a muscle-specification-binding protein | |
GB0202748D0 (en) | Protein | |
GB0204735D0 (en) | Protein | |
GB0221470D0 (en) | Protein fractionation methods for proteomics | |
GB0228311D0 (en) | A new protein | |
GB0230023D0 (en) | A new protein | |
GB0316789D0 (en) | Protein assembly | |
GB0216987D0 (en) | Xylanase binding proteins | |
GB0316380D0 (en) | Control interface | |
GB0202669D0 (en) | Protein | |
GB0202666D0 (en) | Protein | |
GB0207645D0 (en) | Protein | |
GB0207471D0 (en) | Protein | |
GB0207470D0 (en) | Protein | |
GB0206867D0 (en) | Protein | |
GB0205811D0 (en) | Protein | |
GB0205268D0 (en) | Protein | |
GB0205266D0 (en) | Protein | |
GB0205257D0 (en) | Protein |